Resources
174 Results (showing 1 - 10)
Results sorted by updated date (oldest first)
Results sorted by updated date (oldest first)
Posted 10/3/2019 (updated 3/25/2024)
Findings suggest that many North Carolina LEOs understand the public health benefits of syringe access programs and may be inclined to support syringe decriminalization legislation.
Posted 10/7/2019 (updated 3/25/2024)
Mapping Your Way from Vision to Impact: Strategic Planning Tools and Tips (Panel Discussion) Presentation and Resources.
Posted 10/7/2019 (updated 3/25/2024)
The Adopting a Shared Framework for Community Collaboration webinar addresses new questions and comments about the development of a shared public health framework, strategic planning, consortium partners, and opioid use disorder treatment.
Posted 10/7/2019 (updated 3/25/2024)
Mapping Your Way from Vision to Impact: Strategic Planning Tools and Tips Webinar Presentation and Materials
Posted 10/7/2019 (updated 3/25/2024)
An Introduction to Harm Reduction Webinar Presentation and Materials
Posted 11/19/2019 (updated 3/25/2024)
Although typically delivered via intramuscular or intravenous injection, naloxone may be delivered via intranasal spray device.
Posted 11/19/2019 (updated 3/25/2024)
The document provides guidance on how to plan for an outbreak of HIV or HCV among PWID including considerations for developing an outbreak response plan to minimize the impact of the outbreak on the community and stop further transmission. The document also outlines strategies to detect and investigate a possible outbreak.
Posted 1/5/2022 (updated 3/26/2024)
This brief reviews the history, harms, pathways and trends that treat children as if they were adults
Posted 2/9/2022 (updated 3/26/2024)
Summary of innovation abstracts that were presented at the National Academy of Medicine’s recent Stigma of Addiction Summit.
Posted 7/31/2023 (updated 3/26/2024)
At the end of July 2023, the U.S. Food and Drug Administration approved a second over-the-counter naloxone nasal spray product, RiVive. The agency who received the approval to manufacture the product, Harm Reduction Therapeutics, does not yet have a timeline of availability and decision on pricing.